Company / Shareholders' Equity
ORAMED PHARMACEUTICALS INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$145.3M
FY2025
5-year range
$115.8M / $163.8M
FY2021-FY2025
Trend
-0.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from $19M in FY2020 to $164M in FY2023.
Based on SEC 10-K filings.
$145M in FY2025 with a 5-year CAGR of +49.6%.
Declined from $164M to $145M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -1.4%
- 5-Year CAGR
- +49.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +49.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 0.6% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $145.3M | -0.6% |
| FY2024 | $146.3M | -10.7% |
| FY2023 | $163.8M | +7.9% |
| FY2022 | $151.8M | +31.1% |
| FY2021 | $115.8M | +497.0% |
| FY2020 | $19.4M | -37.7% |
| FY2019 | $31.1M | +18.8% |
| FY2018 | $26.2M | +5.5% |
| FY2017 | $24.8M | +19.4% |
| FY2016 | $20.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026